Studies on the Possible Application of BNCT to Thyroid Cancer
Thyroid cancer may occur as a differentiated or an undifferentiated or anaplasic form. The differentiated forms, such as papillary or follicular carcinomas, are in general of a relatively benign prognosis. Most if not all still have a normal uptake of iodine, and therefore surgical thyroidectomy is completed with a therapeutic dose of 131I. In many cases, these forms are well controlled and complete remission of the tumor is obtained. In other instances, the prognosis is not so good. The undifferentiated (UTC) form or the recurrence of some differentiated forms of this pathology has lost their capability to concentrate radioiodine, and therefore the therapeutic dose of this halogen is useless. These last forms are very aggressive and have a fatal outcome in rather a short time after their diagnosis. As a consequence, new treatments are being explored in order to offer these patients a better future. Thanks to the advances in the knowledge of their molecular biology, new chemotherapeutic compounds have been developed and are currently being studied in several clinical trials. Besides, we have started some years ago the study of the possibility of the application of BNCT to the treatment of these pathologies [1, 2].
KeywordsThyroid Cancer Neutron Beam Differentiate Thyroid Cancer Relative Biological Effectiveness Follicular Adenoma
The original studies from our laboratory were supported by grants from the National Research Council (CONICET), the National Agency for Science and Technology (FONCyT), the University of Buenos Aires, and the Atomic Energy Commission. All authors are established researchers from CONICET.
- 11.Dagrosa MA, Thomasz L, Longhino J, Perona M, Calzetta O, Blaumann H, Jiménez Rebagliati R, Cabrini RL, Kahl SB, Juvenal GJ, Pisarev MA (2007) Optimization of the application of boron neutron capture therapy (BNCT) to the treatment of undifferentiated thyroid cancer (UTC). Int J Radiat Oncol Biol Phys 69(4):1059–1066PubMedCrossRefGoogle Scholar
- 15.Dagrosa MA, Chung Y, Riley K, Binns P, Kahl S, Pisarev M, Coderre J (2006) Compound biological effectiveness (CBE) factors in human undifferentiated thyroid cancer (UTC). Advances in Neutron Capture Therapy. Proceedings of ICNCT 12, Takamatsu, Kagawa, 2006, pp 157–160Google Scholar
- 16.Dagrosa M, Crivello M, Thorp S, Perona M, Pozzi E, Casal M, Cabrini R, Kahl S, Juvenal G, Pisarev M (2008) Radiobiological studies in a human cell line of undifferentiated thyroid cancer. Proceedings of 13 ICNCT, Florence, 2008, pp 337–340Google Scholar
- 17.Wittig A, Sheu Y, Kaiser GM, Lang S, Jöckel H, Moss R, Stecher-Rasmussen F, Rassow J, Colette L, Sauerwein W (2008) New indications for BNCT? Results from the EORTC trial 11001. Proceedings of 13 ICNCT, Florence, 2008, pp 39–42Google Scholar
- 18.Hiratsuka J, Morita N, Aihara T, Imajo Y, Maruhashi A, Ono K (2006) First clinical trial of boron neutron capture therapy for thyroid cancer. Advances in Neutron Capture Therapy. Proceedings of ICNCT 12, Takamatsu, Kagawa, 2006, pp 7–9Google Scholar